{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T19:14:32Z","timestamp":1788462872080,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01035-6","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:32:06Z","timestamp":1788460326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Environmental Risk Assessment in Pharmaceutical Regulation: A Comparative Review of EMA, U.S. FDA and CDSCO Guidelines"],"prefix":"10.1007","author":[{"given":"A. S.","family":"Sheena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Rajesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fairoosa","family":"Thaikkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"1","key":"1035_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s44280-025-00103-0","volume":"3","author":"AM Vitanza","year":"2025","unstructured":"Vitanza AM, Oliveri Conti G, Ferrante M. Environmental sustainability of healthcare system in the era of one health: a pharmaceuticals residues point of view. One Health Adv. 2025;3(1):36. https:\/\/doi.org\/10.1186\/s44280-025-00103-0.","journal-title":"One Health Adv"},{"issue":"2","key":"1035_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40199-024-00536-9","volume":"32","author":"Z Mazhandu","year":"2024","unstructured":"Mazhandu Z, Mashifana T. Active pharmaceutical contaminants in drinking water: myth or fact? Daru J Pharm Sci. 2024;32(2):925\u201345. https:\/\/doi.org\/10.1007\/s40199-024-00536-9.","journal-title":"Daru J Pharm Sci"},{"key":"1035_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12060173","author":"G Parker","year":"2024","unstructured":"Parker G, Miller FA. Tackling pharmaceutical pollution along the product lifecycle: roles and responsibilities for producers, regulators and prescribers. Pharmacy. 2024. https:\/\/doi.org\/10.3390\/pharmacy12060173.","journal-title":"Pharmacy"},{"key":"1035_CR4","unstructured":"Guideline on the environmental risk assessment of medicinal products for human use."},{"key":"1035_CR5","unstructured":"Ayscough NJ, Fawell J, Franklin G. Review of human pharmaceuticals in the environment. Environment Agency; 2000."},{"key":"1035_CR6","unstructured":"Environmental Impact Review at CDER | FDA [Internet]. [cited 2026 Aug 8]. Available from: https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/environmental-impact-review-cder?utm_source=chatgpt.com"},{"issue":"1656","key":"1035_CR7","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2013.0587","volume":"369","author":"A K\u00fcster","year":"2014","unstructured":"K\u00fcster A, Adler N. Pharmaceuticals in the environment: scientific evidence of risks and its regulation. Philos Trans R Soc B Biol Sci. 2014;369(1656):20130587. https:\/\/doi.org\/10.1098\/rstb.2013.0587.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"1035_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105437","volume":"142","author":"D Gildemeister","year":"2023","unstructured":"Gildemeister D, Moermond CTA, Berg C, Bergstrom U, Bielsk\u00e1 L, Evandri MG, et al. Improving the regulatory environmental risk assessment of human pharmaceuticals: required changes in the new legislation. Regul Toxicol Pharmacol. 2023;142:105437. https:\/\/doi.org\/10.1016\/j.yrtph.2023.105437.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"1035_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/life15091341","volume":"15","author":"S Zampelli","year":"2025","unstructured":"Zampelli S, Verna R. Environmental pollution from pharmaceuticals. Life. 2025;15(9):1341. https:\/\/doi.org\/10.3390\/life15091341.","journal-title":"Life"},{"issue":"10","key":"1035_CR10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.oneear.2022.09.009","volume":"5","author":"ABA Boxall","year":"2022","unstructured":"Boxall ABA, Wilkinson JL, Bouzas-Monroy A. Medicating nature: are human-use pharmaceuticals poisoning the environment? One Earth. 2022;5(10):1080\u20134. https:\/\/doi.org\/10.1016\/j.oneear.2022.09.009.","journal-title":"One Earth"},{"key":"1035_CR11","doi-asserted-by":"publisher","DOI":"10.1787\/3854026c-en","volume-title":"Management of pharmaceutical household waste: limiting environmental impacts of unused or expired medicine","author":"OECD","year":"2022","unstructured":"OECD. Management of pharmaceutical household waste: limiting environmental impacts of unused or expired medicine. OECD Publishing; 2022. https:\/\/doi.org\/10.1787\/3854026c-en."},{"issue":"4","key":"1035_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/etc.3339","volume":"35","author":"T Aus Der Beek","year":"2015","unstructured":"Aus Der Beek T, Weber FA, Bergmann A, Hickmann S, Ebert I, Hein A, et al. Pharmaceuticals in the environment\u2014global occurrences and perspectives. Environ Toxicol Chem. 2015;35(4):823\u201335. https:\/\/doi.org\/10.1002\/etc.3339.","journal-title":"Environ Toxicol Chem"},{"issue":"2","key":"1035_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.aquatox.2005.09.009","volume":"76","author":"K Fent","year":"2006","unstructured":"Fent K, Weston AA, Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol. 2006;76(2):122\u201359. https:\/\/doi.org\/10.1016\/j.aquatox.2005.09.009.","journal-title":"Aquat Toxicol"},{"issue":"3","key":"1035_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/etc.5535","volume":"43","author":"R Oldenkamp","year":"2024","unstructured":"Oldenkamp R, Hamers T, Wilkinson J, Slootweg J, Posthuma L. Regulatory risk assessment of pharmaceuticals in the environment: current practice and future priorities. Environ Toxicol Chem. 2024;43(3):611\u201322. https:\/\/doi.org\/10.1002\/etc.5535.","journal-title":"Environ Toxicol Chem"},{"issue":"1\u20132","key":"1035_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0378-4274(02)00071-1","volume":"131","author":"R L\u00e4nge","year":"2002","unstructured":"L\u00e4nge R, Dietrich D. Environmental risk assessment of pharmaceutical drug substances\u2014conceptual considerations. Toxicol Lett. 2002;131(1\u20132):97\u2013104. https:\/\/doi.org\/10.1016\/S0378-4274(02)00071-1.","journal-title":"Toxicol Lett"},{"key":"1035_CR16","unstructured":"Environmental risk assessment of medicinal products for human use - Scientific guideline | European Medicines Agency (EMA) [Internet]. 2006 [cited 2026 Feb 17]. Available from: https:\/\/www.ema.europa.eu\/en\/environmental-risk-assessment-medicinal-products-human-use-scientific-guideline"},{"issue":"1","key":"1035_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12302-019-0198-9","volume":"31","author":"R Whomsley","year":"2019","unstructured":"Whomsley R, Brendler-Schwaab S, Griffin E, Jensen J, Moermond C, Scholz B, et al. Commentary on the draft revised guideline on the environmental risk assessment of medicinal products for human use. Environ Sci Eur. 2019;31(1):17. https:\/\/doi.org\/10.1186\/s12302-019-0198-9.","journal-title":"Environ Sci Eur"},{"key":"1035_CR18","unstructured":"Research C for DE and. Environmental Assessment of Human Drug and Biologics Applications [Internet]. FDA; 2025 [cited 2026 Feb 17]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/environmental-assessment-human-drug-and-biologics-applications"},{"key":"1035_CR19","doi-asserted-by":"publisher","unstructured":"OECD. Pharmaceutical Residues in Freshwater: Hazards and Policy Responses. OECD Stud Water. 2019. https:\/\/doi.org\/10.1787\/c936f42d-en","DOI":"10.1787\/c936f42d-en"},{"issue":"1656","key":"1035_CR20","doi-asserted-by":"publisher","first-page":"20130586","DOI":"10.1098\/rstb.2013.0586","volume":"369","author":"RS Kookana","year":"2014","unstructured":"Kookana RS, Williams M, Boxall ABA, Larsson DGJ, Gaw S, Choi K, et al. Potential ecological footprints of active pharmaceutical ingredients: an examination of risk factors in low-, middle- and high-income countries. Philos Trans R Soc B Biol Sci. 2014;369(1656):20130586. https:\/\/doi.org\/10.1098\/rstb.2013.0586.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"1035_CR21","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council of 6\u00a0November 2001 on the Community code relating to medicinal products for human use [Internet]. 2025 Jan 1. Available from: http:\/\/data.europa.eu\/eli\/dir\/2001\/83\/2025-01-01"},{"issue":"3","key":"1035_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.yrtph.2006.04.001","volume":"45","author":"R Laenge","year":"2006","unstructured":"Laenge R, Steger-Hartmann T, Schweinfurth H. The environmental risk assessment of human pharmaceuticals in the overall EU regulatory affairs process. Regul Toxicol Pharmacol. 2006;45(3):223\u20138. https:\/\/doi.org\/10.1016\/j.yrtph.2006.04.001.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"1035_CR23","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1021\/acs.est.5b00302","volume":"49","author":"M \u00c5gerstrand","year":"2015","unstructured":"\u00c5gerstrand M, Berg C, Bj\u00f6rlenius B, Breitholtz M, Brunstr\u00f6m B, Fick J, et al. Improving environmental risk assessment of human pharmaceuticals. Environ Sci Technol. 2015;49(9):5336\u201345. https:\/\/doi.org\/10.1021\/acs.est.5b00302.","journal-title":"Environ Sci Technol"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.scitotenv.2017.06.022","volume":"603","author":"AMPT Pereira","year":"2017","unstructured":"Pereira AMPT, Silva LJG, Lino CM, Meisel LM, Pena A. A critical evaluation of different parameters for estimating pharmaceutical exposure seeking an improved environmental risk assessment. Sci Total Environ. 2017;603:226\u201336. https:\/\/doi.org\/10.1016\/j.scitotenv.2017.06.022.","journal-title":"Sci Total Environ"},{"issue":"7","key":"1035_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18073650","volume":"18","author":"JW Jung","year":"2021","unstructured":"Jung JW, Kang JS, Choi J, Park JW. A novel approach to derive the predicted no-effect concentration (PNEC) of benzophenone-3 (BP-3) using the species sensitivity distribution (SSD) method: suggestion of a new PNEC value for BP-3. Int J Environ Res Public Health. 2021;18(7):3650. https:\/\/doi.org\/10.3390\/ijerph18073650.","journal-title":"Int J Environ Res Public Health"},{"issue":"24","key":"1035_CR26","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/plants14243835","volume":"14","author":"M Paiu","year":"2025","unstructured":"Paiu M, Favier L, Gavrilescu M. Assessing the ecotoxicological effects of emerging drug and dye pollutants on plant-soil systems pre- and post-photocatalytic wastewater treatment. Plants. 2025;14(24):3835. https:\/\/doi.org\/10.3390\/plants14243835.","journal-title":"Plants"},{"issue":"8","key":"1035_CR27","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/etc.3758","volume":"36","author":"JO Straub","year":"2017","unstructured":"Straub JO. Combined environmental risk assessment for the antiviral pharmaceuticals ganciclovir and valganciclovir in Europe. Environ Toxicol Chem. 2017;36(8):2205\u201316. https:\/\/doi.org\/10.1002\/etc.3758.","journal-title":"Environ Toxicol Chem"},{"key":"1035_CR28","unstructured":"BASG [Internet]. [cited 2026 Mar 3]. ERA human. Available from: https:\/\/www.basg.gv.at\/en\/companies\/marketing-authorisation-life-cycle\/faq-marketing-authorisation-life-cycle\/environmental-risk-assessment-era\/era-human"},{"key":"1035_CR29","unstructured":"European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure."},{"key":"1035_CR30","unstructured":"21 CFR \u00a7 25.31 - Human drugs and biologics. | Electronic Code of Federal Regulations (e-CFR) | US Law | LII \/ Legal Information Institute [Internet]. [cited 2026 Aug 8]. Available from: https:\/\/www.law.cornell.edu\/cfr\/text\/21\/25.31?utm_source=chatgpt.com"},{"key":"1035_CR31","unstructured":"eCFR\u202f:: 21 CFR Part 25\u2014Environmental Impact Considerations [Internet]. [cited 2026 Aug 8]. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-25?utm_source=chatgpt.com"},{"key":"1035_CR32","unstructured":"US EPA O. National Environmental Policy Act Review Process [Overviews and Factsheets] [Internet]. 2013 [cited 2026 Feb 23]. Available from: https:\/\/www.epa.gov\/nepa\/national-environmental-policy-act-review-process"},{"key":"1035_CR33","unstructured":"cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=OTg4OA [Internet]. [cited 2026 Aug 8]. Available from: https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=OTg4OA"},{"key":"1035_CR34","unstructured":"admin. Environmental Risk Assessments (ERAs) for Pharmaceuticals: Global Regulatory Landscape and Implementation - KANDIH BIOSCIENCE [Internet]. 2025 Dec 8 [cited 2026 Feb 23]. Available from: https:\/\/kandih.com\/environmental-risk-assessments-eras-for-pharmaceuticals-global-regulatory-landscape-and-implementation\/"},{"key":"1035_CR35","unstructured":"CPCB | Central Pollution Control Board [Internet]. [cited 2026 Feb 23]. Available from: https:\/\/cpcb.nic.in\/index.php"},{"key":"1035_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/0126673878362406250607104550","volume":"16","author":"PD Pandian","year":"2025","unstructured":"Pandian PD, Kaliyaperumal R. Global and Indian regulatory frameworks for pharmaceutical excipients, APIs, and formulations: challenges and harmonization strategies. Recent Adv Drug Deliv Formul. 2025;16:19. https:\/\/doi.org\/10.2174\/0126673878362406250607104550.","journal-title":"Recent Adv Drug Deliv Formul"},{"key":"1035_CR37","unstructured":"Global Regulatory Agencies & Guidelines\u2014PharmaRegulatory. In\u2014India\u2019s Regulatory Knowledge Hub [Internet]. [cited 2026 Mar 3]. Available from: https:\/\/www.pharmaregulatory.in\/global-regulatory-agencies-guidelines\/?utm_source=chatgpt.com"},{"issue":"S1","key":"1035_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40592-024-00195-1","volume":"42","author":"D Fumagalli","year":"2024","unstructured":"Fumagalli D. Environmental risk and market approval for human pharmaceuticals. Monash Bioeth Rev. 2024;42(S1):105\u201324. https:\/\/doi.org\/10.1007\/s40592-024-00195-1.","journal-title":"Monash Bioeth Rev"},{"key":"1035_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2021.152485","volume":"812","author":"M Kumari","year":"2022","unstructured":"Kumari M, Kumar A. Environmental and human health risk assessment of mixture of Covid-19 treating pharmaceutical drugs in environmental waters. Sci Total Environ. 2022;812:152485. https:\/\/doi.org\/10.1016\/j.scitotenv.2021.152485.","journal-title":"Sci Total Environ"},{"key":"1035_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2025.100576","volume":"17","author":"AA Jairoun","year":"2025","unstructured":"Jairoun AA, Al-Hemyari SS, Shahwan M, Alkhoujah S, El-Dahiyat F, Jaber AAS, et al. Towards eco-friendly pharmaceuticals: regulatory and policy approaches for sustainable medicines use. Explor Res Clin Soc Pharm. 2025;17:100576. https:\/\/doi.org\/10.1016\/j.rcsop.2025.100576.","journal-title":"Explor Res Clin Soc Pharm"},{"key":"1035_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106769","volume":"197","author":"H Ahkola","year":"2024","unstructured":"Ahkola H, \u00c4yst\u00f6 L, Sikanen T, Riikonen S, Pihlaja T, Kauppi S. Current uncertainties and challenges of publicly available pharmaceutical environmental risk assessment data. Eur J Pharm Sci. 2024;197:106769. https:\/\/doi.org\/10.1016\/j.ejps.2024.106769.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1035_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1476-069X-6-20","volume":"6","author":"SZ Rahman","year":"2007","unstructured":"Rahman SZ, Khan RA, Gupta V, Uddin M. Pharmacoenvironmentology \u2013 a component of pharmacovigilance. Environ Health. 2007;6(1):20. https:\/\/doi.org\/10.1186\/1476-069X-6-20.","journal-title":"Environ Health"},{"key":"1035_CR43","unstructured":"OECD [Internet]. [cited 2026 Mar 3]. Risk management, risk reduction and sustainable chemistry. Available from: https:\/\/www.oecd.org\/en\/topics\/risk-management-risk-reduction-and-sustainable-chemistry.html"},{"issue":"10","key":"1035_CR44","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1002\/etc.5702","volume":"42","author":"SA Welch","year":"2023","unstructured":"Welch SA, Moe SJ, Sharikabad MN, Tollefsen KE, Olsen K, Grung M. Predicting environmental risks of pharmaceuticals from wholesale data: an example from Norway. Environ Toxicol Chem. 2023;42(10):2253\u201370. https:\/\/doi.org\/10.1002\/etc.5702.","journal-title":"Environ Toxicol Chem"},{"issue":"4","key":"1035_CR45","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1208\/s12248-016-9907-0","volume":"18","author":"T Backhaus","year":"2016","unstructured":"Backhaus T. Environmental risk assessment of pharmaceutical mixtures: demands, gaps, and possible bridges. AAPS J. 2016;18(4):804\u201313. https:\/\/doi.org\/10.1208\/s12248-016-9907-0.","journal-title":"AAPS J"},{"issue":"3","key":"1035_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/etc.5726","volume":"43","author":"KA Kidd","year":"2024","unstructured":"Kidd KA, Backhaus T, Brodin T, Inostroza PA, McCallum ES. Environmental risks of pharmaceutical mixtures in aquatic ecosystems: reflections on a decade of research. Environ Toxicol Chem. 2024;43(3):549\u201358. https:\/\/doi.org\/10.1002\/etc.5726.","journal-title":"Environ Toxicol Chem"},{"key":"1035_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2023.162829","volume":"877","author":"K Bethke","year":"2023","unstructured":"Bethke K, Kropid\u0142owska K, Stepnowski P, Caban M. Review of warming and acidification effects to the ecotoxicity of pharmaceuticals on aquatic organisms in the era of climate change. Sci Total Environ. 2023;877:162829. https:\/\/doi.org\/10.1016\/j.scitotenv.2023.162829.","journal-title":"Sci Total Environ"},{"issue":"1","key":"1035_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/etc.2046","volume":"32","author":"JM Balbus","year":"2013","unstructured":"Balbus JM, Boxall ABA, Fenske RA, McKone TE, Zeise L. Implications of global climate change for the assessment and management of human health risks of chemicals in the natural environment. Environ Toxicol Chem. 2013;32(1):62\u201378. https:\/\/doi.org\/10.1002\/etc.2046.","journal-title":"Environ Toxicol Chem"},{"key":"1035_CR49","unstructured":"OECD [Internet]. [cited 2026 Mar 3]. Environment. Available from: https:\/\/www.oecd.org\/en\/topics\/environment.html"},{"key":"1035_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2022.156305","volume":"839","author":"C Silva","year":"2022","unstructured":"Silva C, Cachada A, Gon\u00e7alves FJM, Nannou C, Lambropoulou D, Patinha C, et al. Chemical characterization of riverine sediments affected by wastewater treatment plant effluent discharge. Sci Total Environ. 2022;839:156305. https:\/\/doi.org\/10.1016\/j.scitotenv.2022.156305.","journal-title":"Sci Total Environ"},{"key":"1035_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2020.110664","volume":"194","author":"P Chaturvedi","year":"2021","unstructured":"Chaturvedi P, Shukla P, Giri BS, Chowdhary P, Chandra R, Gupta P, et al. Prevalence and hazardous impact of pharmaceutical and personal care products and antibiotics in environment: a review on emerging contaminants. Environ Res. 2021;194:110664. https:\/\/doi.org\/10.1016\/j.envres.2020.110664.","journal-title":"Environ Res"},{"key":"1035_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1636269","volume":"12","author":"A Dangy-Caye","year":"2025","unstructured":"Dangy-Caye A, Mousset A, Kermad A, Bouch\u00e9-Bazerolle L, Bujar M, De Lucia ML, et al. Harmonizing health: a global analysis of pharmaceutical regulatory activities by international regulatory organizations. Front Med. 2025;12:1636269. https:\/\/doi.org\/10.3389\/fmed.2025.1636269.","journal-title":"Front Med"},{"key":"1035_CR53","unstructured":"Harmonizing global approaches to chemical risk assessment [Internet]. [cited 2026 Mar 3]. Available from: https:\/\/www.who.int\/activities\/harmonizing-global-approaches-to-chemical-risk-assessment"},{"key":"1035_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fenvs.2024.1488955","volume":"12","author":"LE Miranda","year":"2024","unstructured":"Miranda LE, Shoemaker DJ, Krogman RM. Assessment of pollution and other impairments of US reservoirs based on expert opinion. Front Environ Sci. 2024;12:1488955. https:\/\/doi.org\/10.3389\/fenvs.2024.1488955.","journal-title":"Front Environ Sci"},{"key":"1035_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2023.163301","volume":"880","author":"N Hanna","year":"2023","unstructured":"Hanna N, Tamhankar AJ, Lundborg CS. The development of an integrated environment\u2013human risk approach for the prioritisation of antibiotics for policy decisions. Sci Total Environ. 2023;880:163301. https:\/\/doi.org\/10.1016\/j.scitotenv.2023.163301.","journal-title":"Sci Total Environ"},{"key":"1035_CR56","doi-asserted-by":"publisher","DOI":"10.1787\/f398be90-en","volume-title":"Reinforcing regulatory frameworks through standards, measurements and assurance: making better use of quality infrastructure in policymaking","author":"OECD","year":"2025","unstructured":"OECD. Reinforcing regulatory frameworks through standards, measurements and assurance: making better use of quality infrastructure in policymaking. OECD Publishing; 2025. https:\/\/doi.org\/10.1787\/f398be90-en."},{"issue":"12","key":"1035_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104213","volume":"29","author":"JF Zinken","year":"2024","unstructured":"Zinken JF, Pasmooij AMG, Ederveen AGH, Hoekman J, Bloem LT. Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role. Drug Discov Today. 2024;29(12):104213. https:\/\/doi.org\/10.1016\/j.drudis.2024.104213.","journal-title":"Drug Discov Today"},{"key":"1035_CR58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.chemosphere.2014.01.021","volume":"115","author":"DJ Caldwell","year":"2014","unstructured":"Caldwell DJ, Mastrocco F, Margiotta-Casaluci L, Brooks BW. An integrated approach for prioritizing pharmaceuticals found in the environment for risk assessment, monitoring and advanced research. Chemosphere. 2014;115:4\u201312. https:\/\/doi.org\/10.1016\/j.chemosphere.2014.01.021.","journal-title":"Chemosphere"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01035-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:32:07Z","timestamp":1788460327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-01035-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":58,"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01035-6","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors confirm that there is no conflict of interest in publishing this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}